Company intelligence / Profile preview
Oxeia Biopharmaceuticals
Boston, Massachusetts, United Statesoxeiabiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Oxeia completed a Phase 2a proof-of-concept pilot study for OXE103 at Kansas University Medical Center in fall 2022. The study showed robust treatment effects across all endpoints with an 85% responder rate versus 33% baseline. A Phase 2b study is planned for 2024, which will be randomized, double-blind, and placebo-controlled with 160 participants across multiple U.S. sites[4][6].
- Therapeutic areas
- Neurology
- Modalities
- PeptideLarge molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
University of Kansas Medical Center[8]
Beyond the preview
Go deeper on Oxeia Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxeia Biopharmaceuticals.